

Ensayos Clínicos Cabeza y Cuello abiertos a reclutamiento (actualizado Junio 2020)

Fuente de información: Clinical trials.gov; EU Clinical Trials Register; REEC (AEMPS)

Ensayo/CT-Number	NCT	CODIGO_ESTUDIO	TITULO_ESTUDIO	FASE	INDICACION	ESTADO	MEDICACION	CENTROS	PROMOTOR	ESPECIALIDAD
2019-002922-60	4382109	TTC2019-01/CA209-7HE (INVOTAX)	Phase II Multicenter Randomized Trial to Assess the Efficacy and Safety of First Line Nivolumab in Combination With Paclitaxel in Subjects With R/M HNSCC Unable for Cisplatin-based Chemotherapy (INVOTAX). 1ª LINEA recurrent/metastatic	Phase II	Patients unable for cisplatin-based chemotherapy	RECLUTANDO	INVOLUMAB	ICD_Hospital (BCN) H.U. Clinic (BCN) ICD_Badajoz (BCN) ICD_Girona (BCN) H.Clinico (Madrid) H.12 Octubre (Madrid) H.U. La Fe (Valencia) H.U. Miguel Servet (Zaragoza) C.N.Navarra (Pamplona) H. Lozano Blesa (Zaragoza) H.U. V. Rocio (Sevilla) H. Universitario (Málaga) H.Clinic Valencia H.U.V. Hives (Granada) H.U.V. Salud (Tolosa) C.N. Salamanca C.O. Galicia (Ourense) H.U. Donostia (Sebastian) H.U.M. Valdecilla (Santander) H.U. Lucus Augusti (Lugo)	TTC	Oncología_médica
2018-001437-40	3719690	KO-TIP-007	El estudio AM-HN y SEQ-HN: Estudio pivotal no comparativo de 2 cohortes para evaluar la eficacia de Ipilimumab en pacientes con carcinoma de células escamosas de cabeza y cuello (CCECC) con mutaciones de HRAS (AM-HN) y el impacto de las mutaciones de HRAS en la respuesta a las terapias sistémicas de primera línea para el CCECC (SEQ-HN).	Phase II	Carcinoma de células escamosas de cabeza y cuello (CCECC) recurrente o metastásico con mutaciones en HRAS	RECLUTANDO	Tipifarnib (oral)	H.Vall d'Hebron (BCN) H.U. Clinic (BCN) H.U. San Pau (BCN) ICD_Hospital (BCN) Hidalgo Mar (BCN) H.U. La Paz (Madrid) H.12 Octubre (Madrid) H.U. Sancho (Madrid) H.U. La Fe (Valencia) H.U. Miguel Servet (Zaragoza) C.N.Navarra (Pamplona) H. Santiago de Compostela H.U. V. Victoria (Málaga) H.U. V. Victoria (Málaga) H. Costa del Sol (Málaga)	Kura_Oncology, Inc	Oncología_médica
2018-002513-36	3769206	ASP-1929-301	A Phase 3, Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 Photodynamic Therapy Versus Physician's Choice Standard of Care for the Treatment of Locoregional, Recurrent Head and Neck Squamous Cell Carcinoma in Patients Who Have Failed or Progressed On or After at Least Two Lines of Therapy, of Which at Least One Line Must Be Systemic Therapy.	Phase III	Locoregional, recurrent head and neck squamous cell carcinoma	RECLUTANDO	ASP-1929 Photodynamic therapy	H.U. Sancho (Madrid) H.U. Vall d'Hebron (BCN)	Rakuten Apogyn, Inc	Oncología_médica
2019-003771-38	4109104	MK-7902-010	A Phase 3, Randomized, Placebo-controlled, Double-blind Clinical Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7090/MK-7902) to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib as 1L Intervention in a R/1 Selected Population of Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010).	Phase III	This is a study of pembrolizumab (MK-3475) with or without lenvatinib (E7090/MK-7902) as a first-line intervention in a R/1 selected population with participants with recurrent or metastatic head and neck squamous cell carcinoma.	RECLUTANDO	Pembrolizumab & Lenvatinib	ICD_Hospital (BCN) H.U. Vall d'Hebron (BCN) H.U. San Pau (BCN) H.U. La Paz (Madrid) H.U. L. Biesa (Zaragoza) H.U.V. de Valme (Sevilla)	Merck Sharp & Dohme Corp.	Oncología_médica N-500
2018-000789-13	3669378	ISA101B-HN-01-17	Estudio de fase II, aleatorizado, con doble enmascaramiento y controlado con placebo de cemiplimab en comparación con la combinación de cetuximab más R0128 en el tratamiento de sujetos con cáncer orofaríngeo (COF) VPH-16 positivo resistente al platino	Phase II	Cáncer orofaríngeo (COF) VPH-16 positivo resistente de platino	RECLUTANDO	Human Papilloma Virus (HPV) type 16 E6/E7 synthetic long peptide (SLP) vaccine	ICD_Hospital (BCN) H.U.12 Octubre (Madrid) H.U. Clinica San Carlos (Madrid) H.U. San Chiriac (Madrid) H.U. La Paz (Madrid) H.U. V. Rocio (Sevilla) H.U. V. Victoria (Málaga) H.U. V. Victoria (Málaga) H.U.M. Valdecilla (Santander)	ISA_Therapeutics B.V	Oncología_médica
2015-003589-10	2551159	D419LC00001	A Phase III Randomized, Open-label, Multi-center, Global Study of MEDI4736 Alone or in Combination with Tremelimumab versus Standard of Care in the Treatment of First-Line Recurrent or Metastatic Squamous Cell Head and Neck Cancer Patients	Phase III	Adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) who have not received prior systemic chemotherapy.	ON-HOLD	MEDI4736 Alone or in Combination with Tremelimumab	H.U. Clinic (BCN) H.U. Vall d'Hebron (BCN) ICD_Hospital (BCN) H.U.G. Marañón (Madrid) H.U. C. San Carlos (Madrid) H.U. Lozano Blesa (Zaragoza) H.U. de Javer	AstraZeneca AB	Oncología_médica
2018-001608-12	3645928	IOV-COM-202	Estudio Fase II, multicéntrico de linfocitos de tumores autólogos (LN-144 LN-145) en pacientes con tumores sólidos.	Phase II	Tumores sólidos incluyendo melanoma metastásico avanzado (MM) o inresecable, carcinoma epidermoide de cabeza y cuello avanzado (CECC) y cáncer de pulmón no microcítico (CPNM) - 1ª LINEA o SUCESIVAS	RECLUTANDO	Prolekin (i.v.) / Pembrolizumab	H.U. Vall d'Hebron (BCN) ICD_Durani i Reynals (BCN) H.U.12 Octubre (Madrid) San Chiriac (Madrid) H.U.G. Marañón (Madrid) H.U.F. Jimenez Diaz (Madrid)	ioavance Biotherapeutics Inc	Oncología_médica
2015-004535-12	2383927	KO-TIP-001	An Open Label Phase II Study of Tipifarnib in Advanced Non-Hematological Malignancies With HRAS Mutations	Phase II	Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)/HRAS Mutant Tumor. Other Squamous Cell Carcinoma (SCC) With HRAS Mutant Tumor	RECLUTANDO	Tipifarnib (oral)	H.U. Vall d'Hebron (Barcelona) START H.U. Sancho (Madrid)	Kura_Oncology, Inc	Oncología_médica
2017-005076-26	3485209	SGNTV-001	Open label phase 2 study of Tisotumab Vedotin for locally advanced or metastatic disease in SCCHN TUMORS.	Phase II	4 COHORTS: Colorectal, NSCLC, Exocrine pancreatic adenocarcinoma and SCCHN	RECLUTANDO	Tisotumab vedotin (LV)	H.Vall d'Hebron (BCN) H.U. Ramón y Cajal (Madrid) H.U. Sancho (Madrid) H. Quirónsalud (BCN) ICD_Badajoz (BCN)	Seattle Genetics, Inc	Oncología_médica
2017-000241-49	3207867	CNR1178X2201	A Phase 2, Multi-center, Open Label Study of NRI178 in Combination With PD001 in Patients With Selected Advanced Solid Tumors and Non-Hodgkin Lymphoma	Phase II	NSCLC, Non-Small Cell Lung Cancer, RCC, Renal Cell Cancer, Pancreatic Cancer, Urothelial Cancer, Head and Neck Cancer, DLBCL, Diffused Large B Cell Lymphoma, MDS, Myelodysplastic Colon Cancer, TNBC, Triple Negative Breast Cancer, Melanoma	RECLUTANDO	NRI178 & PD001	H.U. Vall d'Hebron (BCN)	Novartis Pharmaceuticals	Oncología_médica
2015-003385-84	2588267	GO40782 (RXDX-101-02)	An Open Label, Multicenter, Global Phase 2 Basket Study of Entractin for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements	Phase II	Breast Cancer, Cholangiocarcinoma, Colorectal Cancer, Head and Neck Neoplasms (Lymphoma, Large-Cell, Anaplastic), Melanoma, Neuroendocrine, Tumors Non-Small Cell Lung, Cancer/Ovarian Cancer, Pancreatic, Cancer/Papillary Thyroid, Cancer/Myeloid Tumor/Bladder Cell Carcinoma Sarcoma, Salivary Gland Cancers Adult Solid Tumor	RECLUTANDO	ENTRECTINIB	H.U. Vall d'Hebron (BCN) H.U. Ramón y Cajal (Madrid) H.U. Sancho (Madrid) H.U. V. Victoria (Málaga) H.U. C. San Carlos (Madrid) H.U. Virgen Rocio (Sevilla)	Hoffmann-La Roche/Genentech, Inc	Oncología_médica
2017-003182-04	3386721	BP40234	An Open Label, Multicenter, Phase II Study to Evaluate the Therapeutic Activity of RO6874931, an Immunozytoxin, Consisting of Imetelstatin 2 Variant (IL-2v) Targeting Fibroblast Activation Protein-A (FAP), in Combination With Atezolizumab (anti-PD-L1), Administered Intravenously, in Participants With Advanced and/or Metastatic Solid Tumors	Phase II	Advanced/Metastatic: Head and Neck, Oesophageal and Cervical Cancers	RECLUTANDO	RO6874931; Atezolizumab; Gemtuzumab; & Nivolumab	Clinica U. Navarra Hospital del Mar (BCN) H.U. Ramón y Cajal START_Fundación Jimenez Diaz START_Sanchinarro H.Clinic U. Valencia	Hoffmann-La Roche	Oncología_médica
2018-001958-25	3625323	TACT1-002(PH16)KEYNOTE-PTN76	TACT1-002 (Two Active Immunotherapeutics): A multicenter, open label, Phase II study in patients with previously untreated unresectable or metastatic non-small cell lung cancer (NSCLC), or recurrent PD-L1 refractory NSCLC or with recurrent or metastatic squamous head and neck cancer (HNSCC) receiving the soluble LAG-3 fusion protein effligmod alpha (MPS21) in combination with pembrolizumab (PD-1 antagonist)	Phase II	Recurrent or metastatic squamous head and neck cancer (HNSCC)	RECLUTANDO	MP321 & Pembrolizumab	H.Santa Cruz / Sant Pau (BCN) ICD_Badajoz (BCN) H.U. Vall d'Hebron (BCN) F.J. Diaz (Madrid)	IMMUTEP S.A.S	Oncología_médica
2015-00392-28	2376431	LOXO-TRX-15002(NAVIGATE)	A Phase 2 Basket Study of the Oral TRK Inhibitor Larotrectinib in Subjects With NTRK Fusion-positive Tumors	Phase II	The primary objective of this study is to investigate the efficacy of larotrectinib for the treatment of advanced solid tumors harboring a fusion of neurotrophic tyrosine receptor kinase (NTRK) of types 1-3 in children and adults. Adult B: HRAS Larotrectinib will be administered orally as capsule or liquid solution at a dose of 100 mg twice daily in continuing 28-day cycles.	RECLUTANDO	Larotrectinib (LOXO-101)	H.U. Vall d'Hebron (BCN) H.U. Sancho (Madrid) H.U. V. Victoria (Málaga) H.U. Valdecilla (Santander) H. General de Valencia	Bayer	Oncología Médica 19-203 12 years and older
2017-001139-38	3765918	MK3475-689	Estudio de fase III, aleatorizado y abierto para evaluar pembrolizumab como tratamiento neoadyuvante y en combinación con la asistencia habitual como tratamiento adyuvante en el carcinoma epidermoide de cabeza y cuello locoregionalmente avanzado (ECC LA), extirpable, en estado III-IVA.	Phase III	carcinoma epidermoide de cabeza y cuello locoregionalmente avanzado (ECC LA), extirpable, en estado III-IVA	RECLUTANDO	Pembrolizumab (iv) / Ceplatin	H.U. de Santiago H.U. La Paz (Madrid) H.U. V. Rocio (Sevilla) ICD_Hospital (BCN) ICD_Badajoz (BCN) H.U. Vall d'Hebron (BCN)	Merck Sharp & Dohme Corp.	Oncología_médica N-704
2017-003302-40	3452137	W040242	Estudio Fase III multicéntrico, aleatorizado, doble ciego, controlado con placebo de Atezolizumab en ensayo Anti-PD-L1 como terapia adyuvante tras terapia local definitiva, en pacientes con carcinoma de cabeza y cuello de células escamosas con alto riesgo localmente avanzado.	Phase III	Carcinoma localmente avanzado de células escamosas de la cabeza y el cuello (CCECC)	RECLUTANDO	Atezolizumab (iv)	ICD_Badajoz (BCN) ICD_Hospital (BCN) H.U. Clinic (BCN) H.U.12 Octubre (Madrid) H.U. C. San Carlos (Madrid) H.U. G. Marañón (Madrid) H.U. La Fe (Valencia) H.U. L. Biesa (Zaragoza) H.U. Salmadica H.U.V. de Valme (Sevilla)	Roche Farma S.A. (Soc. Unipersonal que realiza el ensayo en España y actúa como representante de F. Hoffmann-La Roche LTD)	Oncología_médica

2018-003352-20	3768063	BO40729	An Open Label, Multicenter Extension Study in Patients Previously Enrolled in a Geneset and/or F. Hoffmann La Roche Ltd Sponsored Apremilumab Study (IMbrella B)	Phase IV	Squamous cell carcinoma of head and neck, Solid Tumors, NSCLC, Urothelial carcinoma, Renal cell carcinoma	RECLUTANDO	Atezolizumab	C.U. Navarra H.U. Sanchinarro (Madrid) H.Sabadel (BCN)	Hoffmann-La Roche	Oncología_médica
2017-003702-41	3237325	IDR-0M-02	Estudio pivotal, multinacional, aleatorizado, doble ciego y controlado con placebo, de SO5942 (Dusquetide) para el tratamiento de la mucositis oral en pacientes con carcinoma de células escamosas de cabeza y cuello tratado con quimiorradiación concomitante.	Phase III	Mucositis oral en pacientes con carcinoma de células escamosas de cabeza y cuello tratado con quimiorradiación concomitante. 1.HUENA	RECLUTANDO	Desiquetide + SO5942	H.Val d'Hebron (BCN) ICD-Girona (BCN) H.U. Geroni Ochoa (Loganés) H.Regional de Málaga H.U. Luciano Blesa (Zaragoza) C.A. San Espases (P.M) H.Son Llatzer (P.M)	Soligenix UK Limited	Oncología_médica
2019-002745-38	UK	GTI-4419-202	An Open Label, Multi-Center Study of the Effects of Superoxide Dismutase Mimetic GC4419 when administered to reduce the incidence and severity of Several Oral Mucositis Associated with Chemoradiotherapy for locally Advanced, Non-Metastatic Head and Neck Cancer	UK	To assess the safety and tolerability of GC4419 administered intravenously (IV) to subjects receiving post-operative or definitive therapy with single-agent cisplatin plus Intensity Modulated Radiation Therapy (IMRT) for locally advanced, non-metastatic squamous cell carcinoma (SCC) of the head and neck.	Not yet recruiting (22/06/2020)	GC4419	C.U. Navarra H.Clinic Santiago H.U. Val d'Hebron (BCN) H.U. Ramon y Cajal H.U. Cruces (Barakaldo) H.U. Fundación Madrid C.U. Salamanca H.U. Jaen H.U.V. Aroca (Sevilla) H.U. Sanchinarro (Madrid) ICD_Girona	Galera Therapeutics, INC	Oncología Médica/Biofarmacia
FASES I & FASES I/II										
2016-002729-28	3260023	TG4001.12	A phase II/III trial evaluating the combination of TG4001 and amlurab in patients with HPV-16 positive recurrent or metastatic malignancies and expansion cohort to oropharyngeal squamous cell carcinoma of the head and neck (SCCN)	Phase II/III	HPV-16 positive recurrent or metastatic malignancies including oropharyngeal squamous cell carcinoma of head and neck, cervical cancer, vulvar cancer, vaginal cancer, penis cancer, anal cancer	ON-HOLD	TG4001 & Amlurab	H.U.12 Octubre (Madrid) H.U. Clinic (Madrid) ICD_Badajoz (BCN) H.U.V. Victoria (Málaga) H.U.V. Nieves (Granada) H.U. General d' Valencia	TRANSGENE	Oncología_médica
2017-000625-12	3149549	CTMX-M-2009-001	A Phase 1-2, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults With Metastatic or Locally Advanced Unresectable Solid Tumors (PROCLAIM-CX-2009)	Phase VII	The purpose of this first-in-human study of CX-2009 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-2009 in adult subjects with metastatic or locally advanced unresectable solid tumors. PROCLAIM: PRObody clinical Assessment In Man CX-2009 clinical trial 003	RECLUTANDO	CX-2009	ICD_Hospital (BCN) H.U. Sanchinarro (Pamplona) H.U. San Chisarno (Madrid) I.VD (Valencia)	Cytom Therapeutics	Oncología_médica
2018-000350-67	3637764	ACT16377	Estudio de fase I/II, abierto, multicéntrico, para evaluar la seguridad, eficacia preliminar y farmacocinética de traslatumab (SAR650984) en combinación con atezolizumab o solo traslatumab en pacientes con enfermedades malignas avanzadas	Phase I/II	Otros	RECLUTANDO	trastuzumab (t)-v	ICD_Hospital (BCN) H.U. Clinic (BCN) H.U. Val d'Hebron (BCN) C.U. de Navarra H.U.12 Octubre (Madrid) M. Anderson (Málaga) H.U. Sanchinarro (Madrid) Unidad Start_DCCC (Madrid) Unidad Start_FIDAZ (Madrid)	Sanoofi, events, research & Development	Oncología_médica
2016-004989-25	3126110	INCAGN1876-201	Estudio de fase III sobre la seguridad, la tolerabilidad y la eficacia de INCAGN1876 en combinación con inmunoterapia en sujetos con neoplasias malignas avanzadas o metastásicas	Phase VII	F: cáncer cuello uterino, endometrio, gástrico, carcinoma hepatocelular, melanoma (mucosal o cutáneo), carcinoma células Merkel, mesotelioma, cáncer colorrectal, carcinoma pulmón no microcítico, cáncer ovario, carcinoma epidermoide cabeza/cuello, cáncer microcítico pulmonar, carcinoma del testículo, cáncer mama triple negativo y carcinoma urinario avanzados o metastásicos. FII: cáncer endometrio, gástrico y CEC avanzados o metastásicos, (tumores alternativos autorizados Monitor médico). 2.HUENA	RECLUTANDO	INCAGN1876	ICD_Badajoz (BCN) H.U. Clinic (BCN) H.U. Val d'Hebron (BCN) H.U.12 Octubre (Madrid) H.U. Ramon y Cajal (Madrid) H.U. Sanchinarro (Madrid) H.U. Victoria (Málaga) H.U. Reina Sofía (Girona) H.U.M. Valdecilla (Santander) C.U. Navarra (Pamplona)	Novartis Biociences International S.A.	Oncología_médica
2017-001475-23	3288962	GO38733	A phase 1a/1b, open-label, dose escalation study of the safety and PK of ROT198457 as a single-agent and in combination with Atezolizumab in patients with locally advanced or metastatic Tumors.	Phase 1a/1b	8. COHORTS: Melanoma, Bladder Ca, NSCLC, Colorectal, Triple Negative Breast Ca, Renal Ca, HbLN Cancer, other Solid Cancers.	RECLUTANDO	Atezolizumab (iv) ROT198457	H.U. Val d'Hebron (BCN) C.U. de Navarra (Pamplona)	Genentech, INC	Oncología_médica
2018-003402-63	3917381	GCT1046-01	First-in-human, Open-label, dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors	Phase 1, first-in-human (FHM) and an expansion part (phase 2a)	Tumores sólidos malignos: Pacientes con cáncer de pulmón no microcítico (CPNM) recidivante o resistente, avanzado o metastásico, carcinoma de endometrio (CE), carcinoma urinario (CU), cáncer de mama triple negativo (CTMN), carcinoma epidermoide de cabeza y cuello (CECC) o cáncer de cuello uterino, que ya no son aptos para el tratamiento de referencia	RECLUTANDO	GEN1046 (iv)	Clinica U. de Navarra H.U. Val d'Hebron (BCN) START_FIDAZ (Madrid) START_DCCC (Madrid)	Genmab A/S	Oncología_médica
2018-001095-38	3799744	ICO-VCN-HbN_2018	A Phase I Study to Evaluate the Safety, Tolerability, and Efficacy of VCN-01 in Combination With Durvalumab (MDX357) in Subjects With Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck	Phase I	Metastasis & Recurrence	RECLUTANDO	Genetic:VCN-01 Biological: Durvalumab	ICD_Hospital H.U. Val d'Hebron	ICD Collaborators: VCN Biosciences S.L. BioClever 2005 S.L. AstraZeneca	Oncología_médica N=19
2017-002242-77	3509012	D933BC00001(CLOVER)	A Phase I Multicenter Study of Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors (CLOVER)	Phase I	Carcinoma epidermoide de cabeza y cuello (CECC), CPNM y CPM.	ON-HOLD	Durvalumab + Cisplatino	H.U.G. Marañón (Madrid) H.U. Victoria (Málaga) ICD_Badajoz (BCN)	AstraZeneca AB	Oncología_médica
2016-002219-16	2988960	M15-862	A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-927 and ABBV-181, an Immunotherapy, in Subjects With Advanced Solid Tumor	Phase I	Advanced, solid tumors, squamous cell cancer of the head and neck, pancreatic cancer, non-small cell lung cancer, melanoma	RECLUTANDO	ABBV-927 & ABBV-181	H.U. Sanchinarro (Madrid) H.U. Puerta de Hierro (Madrid) H.U. La Fe (Valencia) J. Jimenez Diaz (Madrid)	Abbvie	Oncología_médica
2018-001146-34	3260322	8374-CL-0101	A Phase 1b Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors	Phase I	Advanced and serious forms of cancers such as head and neck cancers, non-small cell lung cancers, prostate cancer, ovarian cancer, colorectal cancer and gastric cancer	RECLUTANDO	ASP8374 & Pembrolizumab	H.U. Clinic (BCN) H.U. Val d'Hebron (BCN) ICD_Hospital (BCN) H.U. Sanchinarro (Madrid) F.U. Diaz STAR Unik (Madrid) C.U. La Fe (Madrid) H.U. Madrid H.U.V. Victoria (Málaga) H.U.V. Aroca (Sevilla)	Asahi Pharma Global Development INC. Asahi	Oncología_médica
2019-000446-36	3894618	SL01-DEL-101	Phase 1 Dose Escalation and Dose Expansion Study of an Agonist Redirected Checkpoint Fusion Protein, SL-27952 (PD-1-Fc-OX40), in Subjects With Advanced Solid Tumors or Lymphoma	Phase I	Squamous Cell Carcinoma of the Head and Neck, Melanoma/Non Small Cell Lung Cancer/Trochlear Carcinoma/Gastric Adenocarcinoma/Gastroesophageal Junction Adenocarcinoma/Squamous Cell Carcinoma of the Anus/Squamous Cell Carcinoma of the Skint/Small Cell Carcinoma/Neuroendocrine Lymphoma/Match Repair Deficient or MSI High Solid Tumors	RECLUTANDO	SL-27952	H.U. Val d'Hebron (Barcelona)	Shattuck Labs, Inc.	Oncología_médica
2011-000495-33	1351101	CLGK974X2101	A Phase I, Open-label, Dose Escalation Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands	Phase I	This primary purpose of this study is to find the recommended dose of LGK974 as a single agent and in combination with FOLFIRI that can be safely given to adult patients with selected solid malignancies for whom no effective standard treatment is available.	RECLUTANDO	Drug: LGK974 Biological: POR001	2 Sites Barcelona 2 Sites Madrid	Novartis Pharmaceuticals	Oncología_médica
UK	4234113	SC103	A Multicenter Open-label Phase 1/2b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Pembrolizumab in Patients With Selected Advanced/Metastatic Solid Tumors	Phase I	HNSCC & Thyroid. A multicenter open-label phase 1/2b study to evaluate the safety and preliminary efficacy of SO-C103 as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors	RECLUTANDO	SO-C103 Pembrolizumab	H.U. Val d'Hebron (BCN)	SOTO	Oncología_médica
2019-000478-45	3893955	M19-037	A Phase 1, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 and ABBV-368 With and Without ABBV-181 in Subjects With Locally Advanced or Metastatic Solid Tumors	Phase I	Advanced Solid Tumors: Triple Negative Breast Cancer (TNBC), Non-small cell lung cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC), Metastatic Solid Tumors	Not yet recruiting (22/06/20)	ABBV-927, ABBV-368, ABBV-181, Docetaxel	H.U. Val d'Hebron (BCN) F. Jimenez Diaz (Madrid) C.I.O. Camp (Madrid)	Abbvie	Oncología_médica
2019-001167-22	4166283	M19-894	A Phase 1b, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tisotumumab and Other Therapy Combinations in Subjects With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma	Phase I	The main objective of this study is to assess safety, tolerability, and pharmacokinetics (PK) of ABBV-368 plus tisotumumab, ABBV-368 plus tisotumumab and nab-paclitaxel, and ABBV-368 plus tisotumumab, nab-paclitaxel, and ABBV-181 in participants with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).	Not yet recruiting (22/06/2020)	Drug: ABBV-368 Drug: Tisotumumab Drug: Nab-paclitaxel Drug: ABBV-181	H.U. Clinic (BCN) H.U. Fundación Madrid H.U.12 Octubre (Madrid) Start_San Chisarno (Madrid) H.U. Virgen Victoria (Málaga)	Abbvie	Oncología_médica